plasma protein fraction

REMS

Expansion of plasma volume and maintenance of cardiac output in situations associated with deficiencies in circulatory volume, including:
- Shock,
- Hemorrhage,
- Burns.
Temporary replacement therapy in edema associated with low plasma proteins, such as the nephrotic syndrome and end-stage liver disease.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Allergic reactions to albumin;
Severe anemia;
HF;
Normal or increased intravascular volume;
Cardiopulmonary bypass procedures.

Use Cautiously in:

Severe hepatic or renal disease;
Rapid infusion (may cause hypotension or hypertension);
Dehydration (additional fluids may be required);
Large doses (may cause anemia, requiring transfusion).

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypotension, tachycardia, vascular overload

Derm: erythema, urticaria

GI: excess salivation, nausea, vomiting

MS: back pain

Neuro: headache

Misc: chills, fever, flushing, infection

Interactions ⬆ ⬇

Drug-drug:

None significant.

Availability ⬆ ⬇

Injection: 5% in 50-; 250-; and 500-mL containers

Route/Dosage ⬆ ⬇

Dose is highly individualized and depends on condition being treated. Contains 130–160 mEq sodium/liter. Not to exceed 250 g/24 hr
IV (Adults ): Hypovolemia: 250–500 mL (12.5–25 g protein). Hypoproteinemia: 1000–1500 mL (50–75 g protein).
IV (Infants and Young Children): Hypovolemia: 10–30 mL/kg (0.5–1.5 g protein/kg).

US Brand Names ⬆ ⬇

Plasmanate, Plasma-Plex, Plasmatein, Protenate

Action ⬆ ⬇

Provides colloidal osmotic pressure (in the form of albumin and globulins) within the intravascular space, causing the shift of water from extravascular tissues back into the intravascular space.

Therapeutic effects:

Mobilization of fluid from extravascular tissue into intravascular space.

Classifications ⬆ ⬇

Therapeutic Classification: volume expanders

Pharmacologic Classification: blood products

Pharmacokinetics ⬆ ⬇

Absorption: Administered IV only, resulting in complete bioavailability.

Distribution: Stays mainly in the intravascular space.

Metabolism/Excretion: Unknown.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(intravascular volume expansion)

ROUTE	ONSET	PEAK	DURATION
IV	15–30 min	unknown	unknown

Patient/Family Teaching ⬆ ⬇

Explain the rationale for use of this solution to the patient.

Pronunciation ⬆ ⬇

PLAZ-maPROE -teen FRAK-shun

Code ⬆

NDC Code

13533- GRIFOLS USA, LLC
- 13533-613- Plasmanate
  - 13533-613-20- 1 VIAL in 1 CARTON (13533-613-20) > 50 mL in 1 VIAL (13533-613-21)

13533- GRIFOLS USA, LLC
- 13533-613- Plasmanate
  - 13533-613-25- 1 VIAL in 1 CARTON (13533-613-25) > 250 mL in 1 VIAL (13533-613-26)

13533- GRIFOLS USA, LLC
- 13533-613- Plasmanate
  - 13533-613-27- 1 VIAL in 1 CARTON (13533-613-27) > 500 mL in 1 VIAL (13533-613-28)

section name header

Indications ⬇